Lexicon Pharmaceuticals EV/EBIT LXRX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 12.5×; Nov 2021
Peer median: 6.3×

Lexicon Pharmaceuticals has no meaningful EV/EBIT today: it made an operating loss of $54.5M over the last twelve months.

It was last meaningful in Nov 2021, at 12.5×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	12.5×	8.3×	279×
2020	1.5×	0.8×	2.3×
2019	2.0×	1.6×	2.3×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	279×	216×	291×

Against its peers

Companies in Drug Manufacturers - General nearest Lexicon Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
LXRXLexicon Pharmaceuticals	n/m
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
IRWDIronwood Pharmaceuticals	3.5×
PBYIPuma Biotechnology	15.6×
COLLCollegium Pharmaceutical	9.4×
ABUSArbutus Biopharma	4.9×
ARVNArvinas	n/m
AMPHAmphastar Pharmaceuticals	12.2×
OMEROmeros	n/m
PCRXPacira BioSciences	7.6×
Peer median	6.3×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Lexicon Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.